Epsilon Healthcare says it is enjoying a ramp-up in activities. Almost as much as it would have loved seeing its stock price surge 25 per cent.
In addition, the Australian Office of Drug Control has granted the company increased manufacturing quantities, to meet the growing demand.
Epsilon says it has seen a ramp-up in activities, which reflects the changing needs of the industry and client demand.
For the latest health/biotech news, sign up here for free Stockhead daily newsletters
The company owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport, Queensland Facility).
The company also has a strategic partnership with The Valens Company (NASDAQ: VLNS), a leading cannabis consumer products business with significant expertise in manufacturing cannabinoid-based products, to operate and manage the facility.
“As we continue to grow, we remain committed to delivering our clients and patients with the highest quality medicines possible, and the exceptional level of care that they come to expect from us, especially given the new TGA reforms to apply from July,” said EPN’s release today.
MORE FROM STOCKHEAD: Gemini exchange lists Pepe | Ordinals and BRC-20 tokens explained | What’s the story with Frogsh*t?
Other health news
Biotron (ASX:BIT) says the company’s Phase 2 Covid-19 trial for lead antiviral drug BIT225 had extended to include a second trial site in Thailand.
This follows receipt of approval from the Khon Kaen University Ethics Committee for Human Research.
The Phase 2 trial is a double blind, placebo-controlled clinical trial (BIT225-012) to determine if seven days of treatment with BIT225, started within three days of onset of Covid-19 symptoms, results in the reduction of SARS-CoV-2 blood viral load.
The trial will also look for favourable changes in viral, inflammatory and immune activation markers, as well as improvement in clinical symptoms of Covid-19.
Visit Stockhead, where ASX small caps are big deals
The BIT225 drug already has an established safety profile in human trials, and animal studies have shown it to have both antiviral and immune modulatory activity against SARS-CoV-2.
The company believes it has the potential to be an important first-in-class drug for Covid-19 treatment.
“There remains a need for new, effective oral drugs to treat infection and prevent severe disease,” said Biotron CEO, Dr Michelle Miller.
“We are now focused on enrolment and dosing with the aim of completing the trial as quickly as possible.”
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here